Period October – December 2021
• Net sales: 84,042 (0) TSEK.
• Other operating revenues: 1,098 (3,171) TSEK.
• Profit from financial items: 57,448 (-10,964) TSEK.
• Earnings per share: 2.90 (-1.22) SEK.
Period January – December 2021
• Net sales: 84,042 (0) TSEK.
• Other operating revenues: 7,478 (12,029) TSEK.
• Profit from financial items: 20,965 (-29,551) TSEK.
• Earnings per share: 1.21 (-3.31) SEK.
• Liquidity as per the end of the reporting period: 136,744 (48,895) TSEK.
• Equity ratio as per the end of the reporting period: 95 (89)%.
• The board proposes that no dividend will be paid for the 2021 financial year.
October-December 2021
• CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01. The agreement with Spark has a potential value of USD 328.5 million excluding royalties, with USD 8.5 million upon signing and up to USD 50 million at preclinical and clinical milestones.
• CombiGene’s Horizon 2020 project successfully completed with a final payment of approximately EUR 500,000, which means that CombiGene has received the full grant of EUR 3.36 million.
• CombiGene and Spark Therapeutics communicate plan to expand the clinical development program beyond the EU, to also include the U.S. This also expands the preclinical program.
Events after the end of the period
• GMP production of CG01 made available for preclinical studies planned to enable First in Human study.
• CombiGene signs agreement with University of Michigan to evaluate the leading gene therapy candidate within the lipodystrophy project CGT2.